ITN T-OP Training Network for Optimizing Adoptive T cell Therapy of Cancer, funded by Marie Skłodowska-Curie program, H2020 with Grant Agreement no 955575.
CALL FOR ONE POSITION AS EARLY STAGE RESEARCHER IN HERLEV, DENMARK
Offer description
T-OP Training Network for Optimizing Adoptive T cell Therapy in Cancer is an Initial Training Network funded by the European Union. It started on March 1, 2021 and has a duration of four years. The network comprises 17 partners, from academia, industry, and public authority, located in seven different countries.
T-OP aims at improving the efficacy and production of cell therapies. It will ensure the training of future experts to develop new therapeutic solutions, providing them with a program of excellence.
Over the last years, cancer immunotherapy – using a patient’s own immune system to fight tumors – has emerged as an important complement to standard treatments. In particular, adoptive T cell therapy (ACT) is a promising form of immunotherapy of cancer, consisting of the collection, transformation, and re-infusion of the patient’s own T cells to fight the cancer.
The generation of such ACT products is a complex but ill-defined process with limited harmonization across production and clinical studies, even for the same indication. Cytokines are a key element of in the production of these products, as they are responsible for the growth and differentiation of T-cells.
There is however a limited understanding as to which cytokines might lead to the best outcome at any of these steps. T-OP targets a pioneering research question: how do cytokines influence the therapeutic outcome of ACT products? T-OP brings together interdisciplinary and cross-sectorial teams spanning large and small-sized companies as well as experts in different aspects of cell therapy, immunology, protein engineering, and bioinformatics.
One open position in Herlev, Denmark: Project 6 (ESR6): Therapeutic potential of MerTK signalling in T cells for cancer therapy. We recently characterized MerTK as a co-stimulatory molecule on CD8 T cells. However, MerTK is expressed by cancer cells as well as innate cells in the tumor micro-environment, which implies that numerous cell types – anti- as well as pro-tumor – may compete for the same MerTK ligand https://pubmed.ncbi.nlm.nih.gov/31664482/. The project aims at clarifying the role of MerTK in T and NK cells for adoptive transfer, and also scrutinize the role of MerTK expression by cells in the tumor microenvironment. In Denmark, Copenhagen, at Region Hovedstaden, University Hospital Herlev, National Center for Cancer Immune Therapy (CCIT-DK; https://www.herlevhospital.dk/ccit-denmark/Sider/default.aspx). Supervisor Professor Per Thor Straten.
We seek: Excellent scientists with a Master’s degree or equivalent in natural sciences or related disciplines (such as medicine or pharmacy); practical skills in modern laboratory work, preferentially combined with experience in animal experiments.
We offer: Cutting edge research projects and training with leading experts in the field of cell therapy; employment contract full-time for three years with the benefits of the EU Marie Skłodowska-Curie program with the possibility of earning a doctoral degree (PhD or equivalent).
Your profile: You must be within your first four years of research experience after completion of your Master’s degree or equivalent; you cannot hold a doctoral degree (except medical doctor) at the time of recruitment; you cannot have spent more than 12 months within the past 36 months in the country where the position you are applying for is located (mobility rule) (i.e. Denmark); you must be proficient in the English language both written and spoken (proof required).
Application procedure
The two-stage application procedure will be carried out in compliance with the Code of Conduct for Recruitment and the Charter for Researchers.
- The first stage consists of sending your documents and filling out the required information within the application portal of T-OP, https://www.portal.graduatecenter.uni-muenchen.de/ocgc/t-op , by Friday April 30th, 2021. Please note that we will only evaluate fully completed application forms that are submitted via the application portal of T-OP before the deadline.
- Second stage: Selected candidates from the first stage will be invited for interview, possibly remotely, with the supervisor of the position for which the candidates have applied.
Deadline: April 30, 2021 at 23:00
Expected start date: September 1, 2021
Read more at: https://euraxess.ec.europa.eu/jobs/616145
Skriv et svar